JAMA Oncol:前列腺癌治疗方法评估

2015-02-23 赵洲 MedSci原创

患有无痛性前列腺癌的许多男性经常选择根治性前列腺切除术或者放射疗法进行治疗。这些患者的生活质量可能遭受到重大损失,因为这些治疗和性、泌尿和(或)直肠毒性有关。由于没有对不固定的药物和治疗类型的影响因素的更好的理解,在这些患者中的预期管理的弥散将会变低。为了确定治疗方法的影响因素和待机处理或主动监测在无痛性前列腺癌治疗中的使用。研究人员使用了SEER(监测、流行病学和最终结果)美国国家老年人医疗保险

患有无痛性前列腺癌的许多男性经常选择根治性前列腺切除术或者放射疗法进行治疗。这些患者的生活质量可能遭受到重大损失,因为这些治疗和性、泌尿和(或)直肠毒性有关。由于没有对不固定的药物和治疗类型的影响因素的更好的理解,在这些患者中的预期管理的弥散将会变低。为了确定治疗方法的影响因素和待机处理或主动监测在无痛性前列腺癌治疗中的使用。

研究人员使用了SEER(监测、流行病学和最终结果)美国国家老年人医疗保险制度链接的数据。共有37621名男性在2004年到2007年被诊断患有前列腺癌,研究人员对其跟踪随访至2009年12月31日。研究人员使用混合影响逻辑回归分析的方法以确定与放疗、手术治疗和待机处理或主动监测相关的因素。最常使用的治疗方案是放疗(57.9%,95%CI 57.4%-58.4%),其次是根治性前列腺切除术(19.1%,95%CI 18.7%-19.5%),采取待机处理或主动监测的占9.6%(95%CI 9.3%-9.9%)。有关病人的人口统计资料和肿瘤特征显著地表明:40%患者接受了前列腺切除术,12%选择了待机处理或主动监测,只有3% 选择放疗。此次研究表明放疗的使用在逐渐增多。主动监测没有得到充分利用。对为何选择各种治疗方法的原因的进一步研究是有必要的。

Charles L. Bennett博士等人撰文评论此次试验。他表示关于治疗方法的研究报告是有必要的。对于尚未充分利用和过度利用的治疗方法仍需要进行研究。比较效果研究是有必要的。

原始出处:

Chamie K, Williams SB, Hu JC. Population-Based Assessment of Determining Treatments for Prostate Cancer. JAMA Oncol. Published online February 19, 2015. doi:10.1001/jamaoncol.2014.192.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1864607, encodeId=2e2c186460e28, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jun 19 09:54:00 CST 2015, time=2015-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23702, encodeId=dde223e02a2, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:31:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17158, encodeId=57871e15896, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:09:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399180, encodeId=422d13991801c, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Wed Feb 25 12:54:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16852, encodeId=dc2516852f0, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Tue Feb 24 11:12:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
    2015-06-19 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1864607, encodeId=2e2c186460e28, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jun 19 09:54:00 CST 2015, time=2015-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23702, encodeId=dde223e02a2, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:31:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17158, encodeId=57871e15896, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:09:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399180, encodeId=422d13991801c, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Wed Feb 25 12:54:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16852, encodeId=dc2516852f0, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Tue Feb 24 11:12:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
    2015-05-16 ljjj1053

    很不错学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1864607, encodeId=2e2c186460e28, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jun 19 09:54:00 CST 2015, time=2015-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23702, encodeId=dde223e02a2, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:31:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17158, encodeId=57871e15896, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:09:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399180, encodeId=422d13991801c, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Wed Feb 25 12:54:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16852, encodeId=dc2516852f0, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Tue Feb 24 11:12:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
    2015-02-27 xiaoai5777

    好文章,超赞

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1864607, encodeId=2e2c186460e28, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jun 19 09:54:00 CST 2015, time=2015-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23702, encodeId=dde223e02a2, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:31:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17158, encodeId=57871e15896, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:09:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399180, encodeId=422d13991801c, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Wed Feb 25 12:54:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16852, encodeId=dc2516852f0, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Tue Feb 24 11:12:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1864607, encodeId=2e2c186460e28, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jun 19 09:54:00 CST 2015, time=2015-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23702, encodeId=dde223e02a2, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:31:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17158, encodeId=57871e15896, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:09:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399180, encodeId=422d13991801c, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Wed Feb 25 12:54:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16852, encodeId=dc2516852f0, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Tue Feb 24 11:12:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
    2015-02-24 orthoW

    不错的文章,学习了

    0

相关资讯

The Lancet Oncology:前列腺癌放疗:推荐标准分次疗法

2007年,来自荷兰伊拉斯谟医学中心肿瘤研究所的Aluwini博士带领研究组进行了一项多中心的随机非劣效性的3期临床试验,旨在探索对前列腺癌患者给予大剂量分割放疗或常规分割放疗后无复发生存期的比较情况。他们将最新的研究进展在线发布于2015年2月3日的the Lancet Oncology杂志上,报告了两组患者出现急性胃肠道和泌尿生殖系统的副作用的情况比较。 在这项由荷兰7个医学中心共同参与的临

Lancet:孙颖浩——中国前列腺癌研究领军人物

一月二十四日的《柳叶刀》杂志特别介绍了我国前列腺癌研究的领军人物,第二军医大学校长和长海医院泌尿外科主任孙颖浩教授。 孙颖浩出生于医生家庭,他的父亲是福建省一个乡村部队医院的内科医生,而他的母亲在药房工作。“那个医院非常小,患者大多数很穷。这也是我学医的主要动力之一,”他回忆道。 孙颖浩的父亲后来成为了这家医院的副院长。医院大约有两百个床位,处理的大多是基础疾病,患者一般只

前列腺癌:PSA筛查程序开发优化

作为检测前列腺癌的一个指标—PSA(前列腺特异性抗原)测试,由于它并不总是明确的,所以在泌尿外科是颇具争议的。一个来自维也纳医科大学综合癌症中心和维也纳总医院的研究团队已经开发了一个新的项目:应用个性化药物筛选的方法弥补了PSA测试的不足。因此,前列腺癌筛查是能够达到一个新的质量水平的。 根据奥地利统计局发布,每年大约有4700位男性患有前列腺癌,而在同一时间段内,这些人中大概有1146人死亡。

BJU International:吸烟会增加患者接受前列腺癌治疗的风险

图 1 前列腺特异性抗原无复发存活率(P=0.003) 图2  吸烟情况的无癌转移存活结果 图3 吸烟与胃溃疡毒性(P=0.02) 在前列腺癌患者中,接受治疗的吸烟患者有增加副作用的风险,并且未来有癌症复发的可能性,甚至会死于前列腺癌。研究结果发表在《英国泌尿科期刊》上,研究表明吸烟可能对前列腺癌患者的健康状况产生负面影响,并导致相关的并发症。 几项研究已经证实吸烟和

前列腺癌患者术后慎吃壮阳药

有时候一个科学假设可能会出错,但科学思想仍旧会前进。一项关于男性前列腺癌的研究就是其中一个例子。 在这项研究中,科学家们发现在对患者进行根治性前列腺切除术后使用治疗勃起功能障碍的药物与癌症的复发具有相关性。   他们对这一结果感到震惊:之前大量的实验研究以及临床观察研究的结果都普遍证明ED类药物在抗前列腺癌方面的积极作用。   "我们感到不可思议,事实完全是相反的,"

PNAS:内皮他丁——治疗前列腺癌的AR抑制剂

近日,来自美国的科学家在著名国际期刊PNAS发表一项最新研究成果,他们发现血管生成抑制剂内皮他丁(Endostatin)除了对血管生成具有抑制作用,还能够抑制前列腺癌细胞中雄激素受体(AR)的转录活性。这一研究成果为进一步探讨内皮他丁的抗肿瘤作用具有重要意义。   目前,尽管针对AR治疗去势抵抗性前列腺癌的治疗方法已经得到一定发展,但治疗效果仍不理想,促使研究人员开发新一代化疗药物,